| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)hexanamide](https://resource.bocsci.com/structure/protac1083.gif) |
BPL-200973 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)hexanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 853.91
Molecular Formula: C43H41F2N7O8S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)propanamide](https://resource.bocsci.com/structure/protac1084.gif) |
BPL-200974 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)propanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 855.88
Molecular Formula: C42H39F2N7O9S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)heptanamide](https://resource.bocsci.com/structure/protac1085.gif) |
BPL-200975 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)heptanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 867.93
Molecular Formula: C44H43F2N7O8S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)octanamide](https://resource.bocsci.com/structure/protac1086.gif) |
BPL-200976 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)octanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 881.96
Molecular Formula: C45H45F2N7O8S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)propanamide](https://resource.bocsci.com/structure/protac1087.gif) |
BPL-200977 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)propanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 899.93
Molecular Formula: C44H43F2N7O10S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)propanamide](https://resource.bocsci.com/structure/protac1088.gif) |
BPL-200978 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)propanamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 943.98
Molecular Formula: C46H47F2N7O11S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide](https://resource.bocsci.com/structure/protac1089.gif) |
BPL-200979 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 988.04
Molecular Formula: C48H51F2N7O12S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-amide](https://resource.bocsci.com/structure/protac1090.gif) |
BPL-200980 |
N-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-amide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1032.09
Molecular Formula: C50H55F2N7O13S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1091.gif) |
BPL-200981 |
N-(3-(5-((1-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 882.95
Molecular Formula: C43H44F2N10O7S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1092.gif) |
BPL-200982 |
N-(3-(5-((1-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 896.98
Molecular Formula: C44H46F2N10O7S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1093.gif) |
BPL-200983 |
N-(3-(5-((1-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 911.01
Molecular Formula: C45H48F2N10O7S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(3-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1094.gif) |
BPL-200984 |
N-(3-(5-((1-(3-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 912.98
Molecular Formula: C44H46F2N10O8S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(7-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1095.gif) |
BPL-200985 |
N-(3-(5-((1-(7-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 925.03
Molecular Formula: C46H50F2N10O7S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1096.gif) |
BPL-200986 |
N-(3-(5-((1-(8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 939.06
Molecular Formula: C47H52F2N10O7S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N-(3-(5-((1-(3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide](https://resource.bocsci.com/structure/protac1097.gif) |
BPL-200987 |
N-(3-(5-((1-(3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide |
|
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 957.03
Molecular Formula: C46H50F2N10O9S
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
 |
BPL-200988 |
P4B |
2485722-76-5 |
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1045.14
Molecular Formula: C50H58F2N10O11S
Density: 1.46±0.1 g/cm3
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
 |
BPL-200989 |
P5B |
2485722-77-6 |
CRBN |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1089.19
Molecular Formula: C52H62F2N10O12S
Density: 1.44±0.1 g/cm3
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N1-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide](https://resource.bocsci.com/structure/protac1100.gif) |
BPL-200990 |
N1-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)glutaramide |
|
VHL |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1011.19
Molecular Formula: C51H56F2N8O8S2
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![N1-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide](https://resource.bocsci.com/structure/protac1101.gif) |
BPL-200991 |
N1-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)adipamide |
|
VHL |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1025.21
Molecular Formula: C52H58F2N8O8S2
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
![(2S,4R)-1-((S)-2-(3-(3-((4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)amino)-3-oxopropoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/protac1102.gif) |
BPL-200992 |
(2S,4R)-1-((S)-2-(3-(3-((4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzyl)amino)-3-oxopropoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
|
VHL |
BRAF V600E |
Inquiry |
|
Molecular Weight: 1041.21
Molecular Formula: C52H58F2N8O9S2
Description: It is a thalidomide-based heterobifunctional PROTAC that induces selective degradation of BRAF-V600E, but not the wild-type BRAF.
|
